|
|
|
Insider
Information: |
Edelman Joseph |
Relationship: |
10% Owner |
City: |
New York |
State: |
NY |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
43 |
|
Direct
Shares |
630,171 |
|
Indirect Shares
|
338,007,264 |
|
|
Direct
Value |
$1,416,558 |
|
|
Indirect Value
|
$2,968,804,075 |
|
|
Total
Shares |
338,637,435 |
|
|
Total
Value |
$2,970,220,633 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
48
|
2
|
Stock
price went up :
|
27
|
2
|
Stock
price went down : |
21
|
0
|
|
|
|
Gain/Loss Ratio : |
1.3
|
2.0
|
Percentage
Gain/Loss : |
-13.2%
|
177.4%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Penwest Pharmaceuticals Co |
PPCO |
10% Owner |
2008-06-23 |
0 |
2008-06-23 |
6,387,546 |
Premium* |
|
Synageva BioPharma Corp |
GEVA |
10% Owner |
|
0 |
2011-11-02 |
0 |
Premium* |
|
Aegerion Pharmaceuticals, Inc. |
AEGR |
10% Owner |
2012-11-01 |
133,133 |
2012-11-29 |
2,595,293 |
Premium* |
|
Acelrx Pharmaceuticals Inc |
ACRX |
10% Owner |
|
0 |
2017-06-19 |
4,533,728 |
Premium* |
|
Amicus Therapeutics Inc |
FOLD |
10% Owner |
|
0 |
2018-10-03 |
20,724,424 |
Premium* |
|
VBI Vaccines Inc |
VBIV |
10% Owner |
|
0 |
2014-07-25 |
2,610,356 |
Premium* |
|
Aldeyra Therapeutics, Inc. |
ALDX |
10% Owner |
|
0 |
2024-04-05 |
9,275,851 |
Premium* |
|
Aravive Inc |
ARAV |
10% Owner |
|
0 |
2017-09-22 |
2,099,563 |
Premium* |
|
Kadmon Holdings, Llc |
KDMN |
10% Owner |
|
0 |
2019-11-18 |
14,636,334 |
Premium* |
|
Zogenix, Inc. |
ZGNX |
10% Owner |
2017-09-29 |
0 |
2018-08-10 |
4,070,357 |
Premium* |
|
Global Blood Therapeutics, Inc. |
GBT |
10% Owner |
2017-12-19 |
0 |
2017-12-19 |
4,889,066 |
Premium* |
|
Corium International, Inc. |
CORI |
10% Owner |
2018-01-16 |
0 |
2018-10-12 |
2,724,686 |
Premium* |
|
Albireo Pharma Inc |
ALBO |
10% Owner |
2018-01-25 |
0 |
2022-10-13 |
1,939,723 |
Premium* |
|
Solid Biosciences Inc |
SLDB |
Director, 10% Owner |
2018-01-30 |
0 |
2024-01-11 |
6,906,646 |
Premium* |
|
La Jolla Pharmaceutical Co |
LJPC |
10% Owner |
2018-02-13 |
0 |
2019-01-08 |
2,253,376 |
Premium* |
|
Motus Gi Holdings Inc |
MOTS |
10% Owner |
2018-02-16 |
0 |
2021-01-22 |
2,660,542 |
Premium* |
|
Quotient Ltd |
QTNTQ |
10% Owner |
2018-05-22 |
0 |
2022-10-31 |
7,945,211 |
Premium* |
|
Dova Pharmaceuticals, Inc. |
DOVA |
10% Owner |
2018-06-04 |
0 |
2019-11-12 |
0 |
Premium* |
|
Meiragtx Holdings Plc |
MGTX |
Director, 10% Owner |
2018-06-08 |
0 |
2024-08-12 |
12,531,103 |
Premium* |
|
Crinetics Pharmaceuticals, Inc. |
CRNX |
10% Owner |
2018-07-20 |
0 |
2022-04-18 |
5,321,032 |
Premium* |
|
Agile Therapeutics Inc |
AGRX |
10% Owner |
2018-07-26 |
0 |
2021-10-13 |
21,654,485 |
Premium* |
|
Verrica Pharmaceuticals Inc. |
VRCA |
10% Owner |
2018-06-19 |
0 |
2023-12-29 |
7,099,182 |
Premium* |
|
Athenex, Inc. |
ATNX |
10% Owner |
2019-05-06 |
0 |
2020-09-14 |
13,532,467 |
Premium* |
|
ADMA Biologics Inc |
ADMA |
10% Owner |
2019-05-21 |
0 |
2021-09-30 |
13,262,375 |
Premium* |
|
Foamix Pharmaceuticals Ltd |
FOMX |
10% Owner |
|
0 |
2019-07-29 |
11,203,881 |
Premium* |
|
Lyra Therapeutics, Inc. |
LYRA |
Director, 10% Owner |
2020-05-05 |
0 |
2023-05-31 |
12,757,563 |
Premium* |
|
VYNE Therapeutics Inc |
VYNE |
10% Owner |
2020-06-09 |
0 |
2021-08-16 |
4,935,057 |
Premium* |
|
Leap Therapeutics, Inc. |
LPTX |
10% Owner |
2020-06-22 |
0 |
2020-06-22 |
8,476,496 |
Premium* |
|
Athira Pharma, Inc. |
ATHA |
Director, 10% Owner |
|
0 |
2023-12-29 |
5,402,964 |
Premium* |
|
Cerevel Therapeutics Holdings, I... |
CERE |
Director |
2020-10-20 |
0 |
2024-02-20 |
10,794,876 |
Premium* |
|
Scynexis Inc |
SCYX |
10% Owner |
2021-01-20 |
0 |
2021-01-22 |
1,800,000 |
Premium* |
|
Landos Biopharma, Inc. |
LABP |
Director, 10% Owner |
|
0 |
2021-02-09 |
17,960,839 |
Premium* |
|
Astria Therapeutics, Inc |
ATXS |
Director |
|
0 |
2024-02-01 |
6,485,420 |
Premium* |
|
Prometheus Biosciences, Inc. |
RXDX |
10% Owner |
2021-03-16 |
0 |
2021-03-16 |
3,314,032 |
Premium* |
|
Rain Therapeutics Inc. |
RAIN |
10% Owner |
2021-04-27 |
0 |
2021-10-12 |
2,487,019 |
Premium* |
|
Nautilus Biotechnology, Inc |
NAUT |
10% Owner |
2021-05-24 |
497,038 |
2021-12-08 |
9,111,151 |
Premium* |
|
Isoplexis Corp |
ISO |
10% Owner |
2021-10-12 |
0 |
2021-10-12 |
3,554,587 |
Premium* |
|
Lianbio |
LIAN |
Director, 10% Owner |
|
0 |
2024-02-15 |
57,575,533 |
Premium* |
|
Acrivon Therapeutics, Inc. |
ACRV |
10% Owner |
|
0 |
2024-04-11 |
5,360,858 |
Premium* |
|
Chembio Diagnostics Inc |
CEMI |
Former 10% Owner |
2023-04-04 |
0 |
2023-04-27 |
0 |
Premium* |
|
Soleno Therapeutics Inc |
SLNO |
10% Owner |
|
0 |
2023-06-06 |
2,207,753 |
Premium* |
|
Cargo Therapeutics, Inc. |
CRGX |
Former 10% Owner |
2023-11-14 |
0 |
2023-11-14 |
333,333 |
Premium* |
|
Orchestra BioMed Holdings Inc. |
OBIO |
10% Owner |
|
0 |
2024-07-11 |
4,592,556 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
306 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 11 of 13
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
ATHA |
Athira Pharma, Inc. |
Director |
|
2020-09-17 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
411,196 |
|
- |
|
ATHA |
Athira Pharma, Inc. |
Director |
|
2020-09-22 |
4 |
A |
$0.00 |
$0 |
I/I |
1,644,785 |
2,055,981 |
0 |
- |
|
ATHA |
Athira Pharma, Inc. |
Director |
|
2020-09-22 |
4 |
B |
$17.00 |
$18,000,008 |
I/I |
1,058,824 |
3,114,805 |
2.25 |
- |
|
CERE |
Cerevel Therapeutics Hold... |
Director |
|
2020-10-20 |
4 |
B |
$10.00 |
$1,141,000 |
I/I |
114,100 |
114,100 |
2.1 |
- |
|
CERE |
Cerevel Therapeutics Hold... |
Director |
|
2020-10-21 |
4 |
B |
$10.09 |
$435,838 |
I/I |
43,195 |
157,295 |
2.1 |
- |
|
CERE |
Cerevel Therapeutics Hold... |
Director |
|
2020-10-27 |
4 |
B |
$10.00 |
$30,000,000 |
I/I |
3,000,000 |
3,157,295 |
2.1 |
- |
|
MGTX |
Meiragtx Holdings Plc |
Director |
|
2020-11-23 |
4 |
B |
$12.85 |
$6,425,000 |
I/I |
500,000 |
6,933,277 |
2.1 |
- |
|
ATHA |
Athira Pharma, Inc. |
Director |
|
2021-01-25 |
4 |
B |
$22.50 |
$6,999,998 |
I/I |
311,111 |
3,425,916 |
2.25 |
- |
|
ATXS |
Astria Therapeutics, Inc |
Director |
|
2021-01-28 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,476,924 |
|
- |
|
LABP |
Landos Biopharma, Inc. |
Director |
|
2021-02-03 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,090,924 |
|
- |
|
LABP |
Landos Biopharma, Inc. |
Director |
|
2021-02-05 |
4 |
B |
$11.14 |
$305,826 |
I/I |
27,453 |
7,077,017 |
2.25 |
- |
|
LABP |
Landos Biopharma, Inc. |
Director |
|
2021-02-08 |
4 |
B |
$16.00 |
$20,000,000 |
I/I |
1,250,000 |
7,049,564 |
2.25 |
- |
|
LABP |
Landos Biopharma, Inc. |
Director |
|
2021-02-08 |
4 |
B |
$11.38 |
$1,503,061 |
I/I |
123,053 |
7,200,070 |
2.25 |
- |
|
LABP |
Landos Biopharma, Inc. |
Director |
|
2021-02-08 |
4 |
A |
$0.00 |
$0 |
I/I |
13,369,728 |
1,770,600 |
0 |
- |
|
LABP |
Landos Biopharma, Inc. |
Director |
|
2021-02-09 |
4 |
B |
$13.80 |
$1,403,559 |
I/I |
99,681 |
7,299,751 |
2.25 |
- |
|
SLDB |
Solid Biosciences Inc |
Director |
|
2021-03-23 |
4 |
B |
$5.75 |
$14,999,996 |
I/I |
2,608,695 |
13,412,552 |
2.25 |
- |
|
NAUT |
Nautilus Biotechnology, I... |
Director |
|
2021-05-20 |
4 |
B |
$10.05 |
$1,607,246 |
I/I |
159,925 |
159,925 |
2.1 |
- |
|
NAUT |
Nautilus Biotechnology, I... |
Director |
|
2021-06-03 |
4 |
B |
$10.05 |
$3,317,003 |
I/I |
330,050 |
489,975 |
2.1 |
- |
|
CERE |
Cerevel Therapeutics Hold... |
Director |
|
2021-07-07 |
4 |
B |
$25.00 |
$5,000,000 |
I/I |
200,000 |
4,843,095 |
2.1 |
- |
|
CERE |
Cerevel Therapeutics Hold... |
Director |
|
2021-08-23 |
4 |
B |
$25.78 |
$1,145,586 |
I/I |
44,437 |
4,887,532 |
2.1 |
- |
|
CERE |
Cerevel Therapeutics Hold... |
Director |
|
2021-08-24 |
4 |
B |
$27.73 |
$1,934,473 |
I/I |
69,761 |
4,957,293 |
2.1 |
- |
|
CERE |
Cerevel Therapeutics Hold... |
Director |
|
2021-08-25 |
4 |
B |
$28.57 |
$1,753,827 |
I/I |
61,387 |
5,018,680 |
2.1 |
- |
|
CERE |
Cerevel Therapeutics Hold... |
Director |
|
2021-08-26 |
4 |
B |
$30.23 |
$2,057,061 |
I/I |
68,047 |
5,086,727 |
2.1 |
- |
|
LIAN |
Lianbio |
Director |
|
2021-11-03 |
4 |
B |
$13.51 |
$36,270,200 |
I/I |
2,270,000 |
27,858,895 |
2.25 |
- |
|
LYRA |
Lyra Therapeutics, Inc. |
Director |
|
2022-04-12 |
4 |
B |
$4.22 |
$24,999,997 |
I/I |
5,924,170 |
7,858,285 |
2.25 |
- |
|
306 Records found
|
|
Page 11 of 13 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|